Two targeted drugs tested in lab models of meningioma
Original title: Combination treatment with RAF/MEK inhibitor avutometinib and FAK inhibitor defactinib in preclinical models of meningioma.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was done in animals, not people. Most findings at this stage never become treatments.
This was only done in lab cells and in mice.
The short version
In lab dishes and in mice, one of these drugs slowed meningioma tumor growth.
What was studied. Researchers tested two drugs, avutometinib and defactinib, on meningioma cells grown in the lab. They also tested them in mice with meningioma tumors, alone and together.
What they found. In lab dishes, the two drugs worked better together in some meningioma cells. Defactinib alone worked in cells with a change in the NF2 gene, but avutometinib did not. In mice, avutometinib alone slowed tumor growth and helped the mice live longer.
What this means, and what it doesn't
What it could mean: Adding the second drug helped control tumors under the skin. It did not help mice with brain tumors live longer. Gene changes in a tumor may one day help doctors pick which drug to try.
What it doesn't mean: This work was done in cells and in mice, not in people. It does not mean these drugs help patients with meningioma. This is early lab research, far from everyday care. It is not a promise of a cure.
Source: PubMed, August 12, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.